Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Ophthalmol. 2013;7:1669-82. doi: 10.2147/OPTH.S28863. Epub 2013 Aug 22.

Current and emerging treatment options for uveal melanoma.

Author information

1
The Henry C Witelson Ocular Pathology Laboratory, McGill University, Montreal, QC, Canada.

Abstract

Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults, with a 10-year cumulative metastatic rate of 34%. The most common site of metastasis is the liver (95%). Unfortunately, the current treatment of metastatic UM is limited by the lack of effective systemic therapy. Options for the management of the primary intraocular tumor include radical surgery as well as conservative treatments in order to preserve visual acuity. For metastatic disease, several approaches have been described with no standard method. Nevertheless, median survival after liver metastasis is poor, being around 4-6 months, with a 1-year survival of 10%-15%. In this review, the authors summarize current and promising new treatments for UM.

KEYWORDS:

choroidal melanoma; eye; metastasis; therapy; treatment; uveal melanoma

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Support Center